Brief: Newbury Pharmaceuticals Strengthens Portfolio With Dalbavancin Powder
June 18 (Reuters) - Newbury Pharmaceuticals AB NEWBRY.ST :
* STRENGTHENS PORTFOLIO WITH DALBAVANCIN POWDER
* REGULATORY FILLING TO TAKE PLACE IN NEAR FUTURE
* LAUNCH IS PLANNED IN SWEDEN
Source text for Eikon: ID:nMFN9qvZD6
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln